Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Chemours (CC) EBT (2016 - 2025)

Chemours has reported EBT over the past 12 years, most recently at -$67.0 million for Q4 2025.

  • Quarterly results put EBT at -$67.0 million for Q4 2025, down 6800.0% from a year ago — trailing twelve months through Dec 2025 was -$290.0 million (down 368.52% YoY), and the annual figure for FY2025 was -$277.0 million, down 185.49%.
  • EBT for Q4 2025 was -$67.0 million at Chemours, down from $38.0 million in the prior quarter.
  • Over the last five years, EBT for CC hit a ceiling of $299.0 million in Q3 2022 and a floor of -$433.0 million in Q2 2023.
  • Median EBT over the past 5 years was $25.5 million (2023), compared with a mean of $14.4 million.
  • Biggest five-year swings in EBT: skyrocketed 425.0% in 2022 and later tumbled 6800.0% in 2025.
  • Chemours' EBT stood at -$330.0 million in 2021, then soared by 79.09% to -$69.0 million in 2022, then fell by 2.9% to -$71.0 million in 2023, then soared by 101.41% to $1.0 million in 2024, then tumbled by 6800.0% to -$67.0 million in 2025.
  • The last three reported values for EBT were -$67.0 million (Q4 2025), $38.0 million (Q3 2025), and -$248.0 million (Q2 2025) per Business Quant data.